{"id":"NCT02579057","sponsor":"Johns Hopkins University","briefTitle":"Sub-Q Versus IV Furosemide in Acute Heart Failure","officialTitle":"Prospective, Randomized, Parallel-Group Pilot Study Comparing IV Furosemide to Subcutaneous Furosemide in Acute Decompensated Heart Failure Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-02","primaryCompletion":"2017-06","completion":"2017-07","firstPosted":"2015-10-19","resultsPosted":"2017-11-17","lastUpdate":"2017-12-18"},"enrollment":40,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congestive Heart Failure"],"interventions":[{"type":"DRUG","name":"Furosemide Injection Solution (SCP-101)","otherNames":["sc Furosemide"]},{"type":"DRUG","name":"Furosemide Injection Solution, USP","otherNames":["IV furosemide"]}],"arms":[{"label":"Furosemide Injection Solution, USP","type":"ACTIVE_COMPARATOR"},{"label":"Furosemide Injection Solution (SCP-101)","type":"EXPERIMENTAL"}],"summary":"This study evaluates the clinical efficacy of subcutaneously administered Furosemide Injection Solution versus intravenous administration of Furosemide Injection, United States Pharmacopeia (USP) in adult patients presenting to a heart failure clinic with decompensated heart failure. Half of the patients will receive a subcutaneously administered Furosemide Injection Solution; the other half will receive an intravenous administration of Furosemide Injection.","primaryOutcome":{"measure":"Urine Output","timeFrame":"6-hour period","effectByArm":[{"arm":"Furosemide IV","deltaMin":1636,"sd":875},{"arm":"Furosemide SC","deltaMin":1515,"sd":1000}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29226816"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Hypokalemia"]}}